Cancer
Malignant Rectal Neoplasm
CI-CAN-00008012Explore in graph →
Top-level388 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008012Explore in graph →
Clinical trials
1,551 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (153)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 |
| clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07068763 | Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer(mRCAT-E) | recruiting | Phase 2 | 52 | Sir Run Run Shaw HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07095439 | Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients | recruiting | Phase 2 | 38 | Ain Shams UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05965531 | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy(TASLARC) | recruiting | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06923345 | Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) | recruiting | Phase 2 | 80 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06718543 | Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer(TRIUNITE-03) | recruiting | Phase 2 | 100 | fan liOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06840665 | MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06812728 | Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients | recruiting | Phase 2 | 100 | Menoufia UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06802666 | Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06793137 | Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06765616 | Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 31 | Feng TianOTHER_GOV | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05601505 | Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer(CINTS-R) | recruiting | Phase 2 | 470 | Peking Union Medical College HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06542588 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC | recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06455124 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT05228431 | Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 121 | Zhen-Hai LuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06234007 | Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06266832 | The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | recruiting | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06254521 | The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer | recruiting | Phase 2 | 60 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | recruiting | Phase 2 | 186 | Beijing Friendship HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05450029 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer(SILAR) | recruiting | Phase 2 | 51 | Yanhong DengOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05939661 | A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer(AMBITION) | recruiting | Phase 2 | 45 | Osaka UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05136326 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer(CATARTIC) | recruiting | Phase 2 | 21 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05563922 | Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma(OP-TNT) | recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jan 16, 2026source: clinicaltrials